Arcturus Therapeutics Holdings Inc. Common Stock (ARCT) is a publicly traded Healthcare sector company. As of May 21, 2026, ARCT trades at $6.76 with a market cap of $199.81M and a P/E ratio of -2.40. ARCT moved +1.94% today. Year to date, ARCT is +7.06%; over the trailing twelve months it is -46.30%. Its 52-week range spans $5.85 to $25.88. Analyst consensus is buy with an average price target of $18.50. Rallies surfaces ARCT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
ARCT financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. ARCT recently traded at $6.76. Market cap is $199.81M. P/E ratio is -2.40. Revenue is $54.71M.
| Metric | Value |
|---|---|
| Price | $6.76 |
| Market Cap | $199.81M |
| P/E Ratio | -2.40 |
| EPS | $-2.83 |
| Dividend Yield | 0.00% |
| 52-Week High | $25.88 |
| 52-Week Low | $5.85 |
| Volume | 208 |
| Avg Volume | 0 |
| Revenue (TTM) | $54.71M |
| Net Income | $-78.67M |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $82.03M | $-65.78M | $-2.40 |
| 2024 | $152.31M | $-80.94M | $-3.00 |
| 2023 | $166.80M | $-29.73M | $-1.12 |
| 2022 | $206.00M | $9.35M | $0.35 |
10 analysts cover ARCT: 0 strong buy, 7 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $18.50.